Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes-Radioactive & Nonradioactive - Dosimetry & Image Analysis

Accuracy of in vivo 90Y activity and dose quantification based on 90Y-PET/CT following 90Y-Radioembolization

E Courtney Henry, Benjamin Lopez and S. Cheenu Kappadath
Journal of Nuclear Medicine June 2023, 64 (supplement 1) P741;
E Courtney Henry
1UT MD Anderson Cancer Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Lopez
1UT MD Anderson Cancer Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Cheenu Kappadath
1UT MD Anderson Cancer Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

P741

Introduction: Quantitative PET can estimate in vivo 90Y-activity and absorbed dose distributions following 90Y-radioembolization (90Y-RE). Due to its low β+ branching ratio (32 ppm), 90Y-PET acquisitions are long (10-20 min/bed) and subject to respiratory motion blur and image coregistration errors, whose impact on the accuracy of 90Y-activity quantification are largely unknown. Furthermore, absorbed doses are estimated in PET by dose kernel-based voxel-S-values (VSV) dosimetry in lieu of local deposition model with known activity (LDM). In this work, we characterize the accuracy of in vivo 90Y-activity estimates (Aimage) relative to administered 90Y-activity (Aadmin) in perfused volumes (PV) and tumor (T) volumes of interest (VOIs). We also investigate differences between DVSV (mean dose from VSV dosimetry) and DLDM (mean dose from LDM dosimetry) in PV and T.

Methods: As part of a prospective 90Y-RE clinical trial RAPY90D (NCT03896646) using TheraSphere, 33 patients underwent 90Y-PET/CT imaging (GE Discovery MI-5ring) using 90Y-radionuclide selection for a single bed 25-minute acquisition. Images were reconstructed with CT-attenuation and scatter corrections using 3D-OSEM (2 IT, 21 SUB) in 2.7x2.7x2.8 mm3 voxels. PV (N=42), PV with 2 cm isotropic expansion (PV2) and T (N=47) VOIs were delineated by an interventional radiologist and used in conjunction with MIM SurePlan LiverY90 for dosimetry and 90Y-activity quantification. Aimage in PV and PV2 were compared to Aadmin using Bland-Altman (BA) analysis, with and without patient-specific lung shunt fraction (LSF) correction. For each comparison, we report correlations, mean bias, standard error (SE), limits of agreement (LOA), and fraction of cases with ±10% and ±20% differences. The ratio of Aadmin to planned activity (Aplan) is also reported. Likewise, we calculated mean bias, SE, and LOA in BA comparisons of DLDM and DVSV in PV and T. Finally, we investigated potential correlations between activity differences for PV (DAPV) and Aadmin and volume, as well as correlations between dose differences for PV and T (DDPV and DDT) and DLDM and volume. In each comparison, Aadmin and DLDM served as the ground truth.

Results: The median (IQR) Aadmin/Aplan was 1.006 (0.007) demonstrating high precision for Aadmin. Although Aadmin and Aimage were correlated (R2>0.93), the mean bias±SE (LOA) between Aimage and Aadmin in PV and PV2 were -33±5% (±32%) and 1±8% (±51%), respectively. A paired t-test showed significant differences between Aadmin andAimage for PV (0.66±0.14 GBq, p<0.01) but not for PV2 (0.08±0.16 GBq, p=0.57). The fraction of cases with ±10%, ±20% differences between Aimage and Aadmin increased from 5% and 19% for PV to 48% and 67% for PV2, respectively. With a median (IQR) LSF of 3.2% (2.9%), there were no significant differences in the mean bias and residual error distribution when Aadmin was adjusted by LSF. DAPV decreased linearly with Aadmin (p<0.01) and with PV volume (p<0.01). In terms of dosimetry for PV and T, DLDM and DVSV were well correlated (R2=0.70 and 0.75) but resulted in a mean bias±SE (LOA) of 23±6% (±36%) and 23±5% (±33%), respectively. Both DDPV and DDT were weakly correlated with DLDM (R2=0.54 and 0.34), but only DDT was correlated with T volume (R2=0.23).

Conclusions: While Aimage was highly correlated with Aadmin for PV and PV2, yet only by accounting for "activity blurring" from respiratory motion and coregistration errors (PV2) wasAimage, on average, found to equal Aadmin. However, 90Y-activity agreement on an individual patient basis (precision) was low with LOA of ±51%. These findings were not affected by LSF correction and Aplan assay variability. The mean bias between Aadmin and Aimage and between DLDM and DVSV was 33% and 23%, respectively, and independent of VOI assessed. The 10% discrepancy observed may be attributed to differences in the specific implementation of VSV dosimetry or differences in TheraSphere activity calibration. Ongoing work is focused on understanding these discrepancies.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 64, Issue supplement 1
June 1, 2023
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Accuracy of in vivo 90Y activity and dose quantification based on 90Y-PET/CT following 90Y-Radioembolization
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Accuracy of in vivo 90Y activity and dose quantification based on 90Y-PET/CT following 90Y-Radioembolization
E Courtney Henry, Benjamin Lopez, S. Cheenu Kappadath
Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) P741;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Accuracy of in vivo 90Y activity and dose quantification based on 90Y-PET/CT following 90Y-Radioembolization
E Courtney Henry, Benjamin Lopez, S. Cheenu Kappadath
Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) P741;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Dosimetry for Ac-225 and Bi-213 labeled cancer therapy agents.
  • SPECT Frame Duration Shortening: Impact on Lu-177 Dosimetry
  • Impact of Segmentation Methods on Healthy Organ and Tumor Activity Estimates for 177Lu-DOTATATE Therapy – Results from SNMMI 177Lu Dosimetry Challenge
Show more Molecular Targeting Probes-Radioactive & Nonradioactive - Dosimetry & Image Analysis

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire